HE BONE MARROW microenvironment contains a
T mixed cell population of macrophages, fibroblasts, and adipocytes'.' referred to collectively as stromal cells. A number of stromal cell lines have been found to support myeloid and lymphoid differentiation and/or proliferation in vitro through direct cell-cell interaction and/or release of cytokines (interleukins and growth factor~),3-~ indicating a critical role for these stromal elements in hematopoiesis.
Interleukin-7 (IL-7) is a 25-Kd glycoprotein that was originally characterized as a product of a cloned murine bone marrow (BM) stromal cell line6s7 and its messenger RNA (mRNA) has since been detected in the thymus and spleen.* Human recombinant IL-7 exhibits a strong degree of homology with murine IL-7 (about 60%) with all of the six cysteine residues con~erved.~ In vitro, IL-7 induces the proliferation of pro-B and pre-B and affects the growth of both immature and mature cells of the T-lymphocyte lineage.''-" IL-7 also has been reported to induce lymphokine-activated killer (LAK) activity from human peripheral blood leukocytes (PBL)1431s and mouse splenocytes'6 in vitro. Much less is known about the in vivo effects of IL-7 on hematopoiesis, although a preliminary report has suggested that splenic granulocyte-macrophage colony-forming units (CFU-GM) are somewhat increased in mice treated with IL-7." Therefore, the aim of these studies was to determine whether the administration of IL-7 to mice could alter the incidence or total number of single and multi-lineage myeloid progenitor cells.
MATERIALS AND METHODS
Mice. C57BL16 or C57BL16-Ly5.1 mice were used at 6 to 8 weeks of age and were obtained from the Animal Production Area of the National Cancer Institute-Frederick Cancer Research and Development Center (Frederick, MD).
Recombinant murine IL-3 was produced by COS-7 cells transfected with a plasmid containing the IL-3 cDNA, then the supernatants were harvested according to a previously described procedure.'* Recombinant human erythropoietin (Epo) was obtained from Amgen (Thousand Oaks, CA). Recombinant IL-2 was generously donated by Cetus Corporation (Emeryville, CA). The IL-2 had a specific activity of 18 x 106 Growth factors and reagents.
analysis showed that most of this IL-7-induced increase in lymphocytes was attributable to an increase in immature B cells (B220+, slg-), while cells expressing the myelomonocytic markers 8C5 and MAC-1 decreased by twofold to threefold. Further studies showed that the administration of IL-7 to mice that had been rendered leukopenic by the injection of cyclophosphamide (Cy) or 5-fluorouracil (5FU) exhibited a more rapid recovery and/or overshoot in their peripheral blood lymphocytes when compared with mice treated with Cy or 5FU alone. These results show that IL-7 can differentially regulate myelopoiesis in the BM and spleen, while stimulating lymphopoiesis. This is a US government work. There are no restrictions on its use.
international (WHO) Ulmg and contained less than 0.012 ng endotoxinlml protein. Recombinant human IL-7, which was produced in Escherichia coli and purified by Immunex Corporation (Seattle, WA), was generously supplied by Sterling Drug, Inc (Malvern, PA). The IL-7 had a specific biologic activity of 2 to 5 X lo7 Ulmg, as measured by proliferation of a murine pre-Eke11 line9; endotoxin levels were less than 0.1 nglmg IL-7. Mice were injected with either Hanks' Balanced Salt Solution (HBSS) + 0.1% normal mouse serum (NMS), IL-7 + HBSS + 0.1% NMS, or IL2 + HBSS + 0.1% NMS. Inactivated IL-7 was generated by heating at 100°C for 1 hour.
BM from mice that had been previously injected intraperitoneally (IP) with IL-2 or IL-7 were flushed with RPMI 1640 from the femurs and tibias of control or cytokine-pretreated mice. The cells were washed twice and resuspended in the a modification of Eagle's minimal essential medium (EMEM) containing 10% fetal bovine serum (FBS; Hyclone, Logan, UT). Spleen cell suspensions were generated by gently pressing the spleens through a fine mesh screen and suspending the cells in HBSS + 0.5% bovine serum albumin (BSA). Red blood cells (RBCs) were removed by water lysis and the leukocytes were washed twice with HBSS + 0.5% BSA. BM or spleen cells were
35
DAMIA ET AL C ' ' plated at 10' or lo6 cells/mL, respectively, in 35-mm Lux petri dishes (Miles Laboratories, Inc, Naperville, IL) containing a 1 mL mixture of EMEM, 20% FBS, 1% L-glutamine, 2 x mol/L hemin, 5 x lo-' mol/L 2-mercaptoethanol (2-ME), 4 to 6 U/mL Epo, 100 U/mL IL-3, and 0.05 mg/mL gentamicin in 0.3% Seaplaque agarose (FMC Bioproducts, Rockland, ME). Dishes were incubated at 37°C in 5% CO, and scored for CFW after 10 days. Multipotential colonies containing granulocyte, erythroid, megakaryocyte, and macrophage lineages are designated as CFU-GEMM, whereas monocyte, myeloid, and myelomonocytic colonies are designed as CFU-c. The data are presented either as CFU per 1 X 105 or 1 x 106 cells for BM or spleen, respectively. In some cases, the data are presented as the total number of CFU obtained from paired femurs and tibias. This calculation is presented as total CFU per mouse.
BM cells were obtained from normal mice treated with either IL-7 or HBSS and stained with Giemsa (EM Sciences, Gibbstown, NJ) and microscopically evaluated for morphology. The analysis was performed by evaluating 300 cells per sample.
Surface phenotype analysis of BM cells. The surface phenotype of BM cells was determined using immunofluorescence labeling followed by flow cytometry analysis. The BM cells were quickly lysed with distilled water to remove RBCs and washed once in HBSS without calcium, magnesium, and phenol red (Whittaker Bioproducts, Walkersville, MD). One million cells per sample were labeled with 10 p L of the optimal concentration of primary antibody in a 96-well round-bottom plate for 15 minutes at 4°C. Cells were washed with HBSS containing 0.1% sodium azide and 0.1% BSA (sorter buffer). When required, this was followed by 15 minutes of incubation at 4°C with 10 KL of the appropriate developing secondary reagent at an optimal concentration and washed again in sorter buffer. The percentage of cells bearing a particular cell surface marker was determined using a Becton Dickinson (Mountain View, CA) FACScan flow cytometry analyzer using a 15-mW Argon-Ion laser with a 488 nm excitation beam. T cells were detected using the anti-CD3 monoclonal antibody (MoAb) 5O0A2l9 developed with a fluorescein-labeled affinity-purified goat antihamster IgG antibody (Caltag, South San Francisco, CA). Natural killer (NK) cells were detected using the MoAb NK1.1"' developed with a fluorescein-labeled affinitypurified goat antimouse IgG, antibody (Fisher Scientific, Orangeburg, NY). Myeloid cells were detected using an anti-MAC-1 MoAb (Hybritech/Boehringer Mannheim, San Diego, CA) developed with a fluorescein-labeled affinity-purified goat antirat IgG heavy and light chain-specific and mouse serum-absorbed antibody (Kirkegaard and Perry Laboratories, Gaithersburg, MD). Granulocytes and immature hematopoietic lineage cells were detected using the biotinylated MoAb RB6-8C5 (8C5) (Pharmingen, San Diego, CA) developed with phycoerythrin-labeled avidin (Becton Dickinson). Mature B cells (surface Ig bearing, sIg) were detected using fluorescein-labeled affinity-purified goat antimouse IgG heavy and light chain-specific antibody (Kirkegaard and Perry Laboratories) and B-lineage cells (mature and immature) were detected using the anti-B220 MoAb 14.8*' developed with fluoresceinlabeled affinity-purified goat antirat IgG heavy and light chainspecific and mouse serum-absorbed antibody (Kirkegaard and Perry Laboratories).
C57BL/6 mice were treated with either 400 mg/kg of cyclophosphamide (Cy) IP or 150 mg/kg 5-fluorouracil (5FU) intravenously (IV). Twenty-four hours later, half of the mice were entered on treatment with IL-7 and half with phosphate-buffered saline (PBS) + 0.1% NMS. All mice were treated twice daily and the dose of IL-7 used was 1 pg/injection. Treatment was continued up to the time each group was euthanized for analysis of PB leukocyte and lymphocyte numbers.
Morphologic analysis of BM cells.
Administrution of IL-7 to leukopenic mice.
Statistical analysis. Statistically significant differences between groups were detected by Student's t-test.
RESULTS
Hematopoietic effects of IL-7as a function of increased time of administration. Mice were initially injected IP with HBSS + 0.1% NMS, IL-2, or IL-7 twice a day for increasing periods of time at a cytokine dose of 10 p,g/injection. The use of human recombinant IL-2, which also affects lymphoid lineages, served as a control for the injection of another human protein into mice. The administration of IL-7 to mice at this dose for up to 7 days did not produce any significant alterations in weight and was not overtly toxic (data not shown). A threefold increase in total white blood cells (WBCs) in the PB was observed after 4 or 7 days of treatment with IL-7, and after 7 days of treatment with IL-2 ( Fig 1A) .
No significant quantitative change in BM cellularity was observed in this experiment (Fig 2A) , yet the number of both CFU-GEMM and CF'U-c BM colonies per 1 x lo5 cells was reduced by about 60% (P < .05) and greater than 95% (I' < .01) in mice treated with IL-7 for 4 and 7 days, respectively (Fig 2A) . Because there was no appreciable change in the overall BM cellularity in this experiment (Fig  2A) , there was an IL-7-induced absolute decrease in the For personal use only. on October 3, 2017. by guest www.bloodjournal.org From quency of myeloid progenitors induced by IL-7 (Fig 3A) . Specifically, the number of CFU-c per 1 x lo6 cells significantly increased by fivefold to 53 * 2 (P < .01) by day 4 and remained elevated (21 2 7; P < .05) at day 7 as compared with 9 2 2 for control mice. Similarly, the frequency of splenic CFU-GEMM significantly (P < .05) increased from less than 1 per 1 x lo6 cells in control mice to 4 * 2 and 3 ? 1 at days 4 and 7, respectively. However, because there was also an increase in the total number of splenic leukocytes, there was an overall greater increase in both CFU-c and CFU-GEMM per organ (Fig 3B) . Specifically, IL-7 increased the total number of splenic CFU-c by 14-fold at days 4 and 7, and the number of CFU-GEMM by fourfold and eightfold at days 4 and 7, respectively. The only schedule by which IL-2 was able to significantly (P < .05) increase the number of splenic progenitors was when IL-2 was administered for 7 days. Thus, IL-7 and IL-2 have different effects on BM progenitor cells, with IL-7 profoundly decreasing the number of both CFU-c and CFU-GEMM progenitors and IL-2 having an inhibiting and total CFU per mouse (B). Mean total leukocyte counts x106 (+) are also presented in the boxes above each treatment group in (A).
total number of CFU-c and CFU-GEMM of about 60% and 95% at days 4 and 7, respectively (Fig 2B) . The total number of CFU-GEMM cultured per mouse was similarly reduced. Mice treated with IL-2 for 7 days had a 55% reduction in BM CFU-GEMM, but no change was seen in the numbers of CFU-c (Fig 2A) . Neither a single day of treatment with IL-7, nor the administration of IL-2 from 1 to 4 days, affected the colony-forming capacity of BM progenitor cells. However, in the spleen, there was up to a fivefold increase in total cellularity. Although IL-7 induced about a twofold increase splenocytes that expressed mature markers, there was a disproportionate 30-fold increase in the number of cells that lacked mature surface markers (surface Ig for B cells, CD3 for T cells, NK1.l for NK cells, and MAC-1 for macrophages/neutrophils) (data not shown).
There was also a twofold to sixfold increase in the fre- For pglinjection and there was no effect at the lowest dose of 0.1 pglinjection. In contrast a significant (P < .005) increase by fourfold to fivefold in the frequency of CFU-c and CFU-GEMM progenitors was observed in the spleen ( Fig  5A) . Because overall cellularity in the spleen was also increased, the total number of both CFU-c and CFU-GEMM in the spleen were increased by about 20-fold compared with mice treated with HBSS (Fig 5B) . A control group that used heat-inactivated IL-7 at a dose of 10 pglinjection also did not exhibit any significant alterations in CFU formation in either the BM or spleen.
Because a twice daily dose of 5 pg induced maximal effects, this dose was used to study the reversibility of the IL-7-induced effects on BM and splenic myeloid progenitor numbers. The WBC counts remained significantly elevated (P < .01) for at least 3 days after the end of the 7-day period of IL-7 administration, with a return to about normal values by day 6 (Fig 1C) . A significant reduction (P < .01) in the frequency of BM CFU-c (Fig 6A) reReversibility of IL-7induced effects on myelopoiesis. effect only on the number of CFU-GEMM after 7 days of treatment. Both cytokines increased extramedullary hematopoiesis, but IL-7 does this more rapidly. The myelopoietic effects of IL-7 were dose-dependent when mice were treated for 7 days (when the maximum effects on the BM were observed). A dose-dependent increase in peripheral WBCs (Fig 1B) was observed. The results in Fig  4A show that daily doses of 5 or 10 pg IL-7Iinjection did not change the BM cellularity, but completely eliminated the formation of BM CFU-GEMM and significantly reduced (P < .001) the number of CFU-c per 1 x los cells (93% and 89%, respectively). Because there was no significant change in BM cellularity after treatment with IL-7 (Fig 4A) , the decreased frequency of progenitors observed after twice daily treatment with 5 kg or 10 pg IL-7 translated into an overall decrease of 90% in the total number of progenitors per mouse for both CFU-c and CFU-GEMM (Fig 4B) . A partial inhibition in BM CFU was seen at a dose of 1 Dose dependency of the myelopoietic effects of IL-7. For personal use only. on October 3, 2017. by guest www.bloodjournal.org From mained evident 3 days after the last injection of IL-7 as compared with HBSS-treated mice (21 * 4 v 48 * 8), while by day 6 this phenomenon was reversed with a tendency towards a rebound and overshoot in CFU-c (83 * 14 v 52 ? 13) and a return to basal level by day 14. Similarly, the IL-7-induced reduction in the total number of CFU in the BM was also reversed by 6 days after the cessation of IL-7 administration (Fig 6B) . In the spleen (Fig 7A) , the IL-7-induced increase in cellularity remained significantly elevated (P < .01) until day 6, and a twofold increase (P < .05) in the frequency of CFU-c colonies was still evident 14 days after the end of IL-7 treatment, while the levels of CFU-GEMM normalized between days 1 and 3. The total number of splenic CFU-GEMM per mouse returned to baseline by day 6, while the total number of CFU-c returned to baseline by day 14 (Fig 7B) .
Morphologic analysis of BM cells obtained from mice treated with ZL-7. Because treatment of mice with IL-7 significantly reduced both the frequency and total number of CFU in the BM in the absence of significant changes in cellularity, morphologic studies were performed to determine whether there were grossly visible changes in the composition of the BM. The results shown in Fig 8 show that the composition of the BM obtained from mice treated with IL-7 (Fig 8C) is morphologically different from that obtained from mice treated with either HBSS (Fig 8A) or inactivated IL-7 (Fig 8B) . Specifically, the marrow obtained from IL-7-treated mice contains approximately 35% lymphocytes, while mice not treated with IL-7 have only about a 10% incidence of lymphocytes. In addition, the percentage of leukocytes that exhibit a segmented nucleus decreases from greater than 30% in mice treated with HBSS or inactivated IL-7 to about 15% in IL-7-treated mice.
Phenotypic analysis of BM cells obtained from mice treated with IL-7. Because the percentage of lymphocytes was increased, and the percentage of cells that exhibit a segmented nucleus was decreased in mice that were treated with IL-7 (Fig 8) , flow cytometry studies were performed to objectively determine changes in subset composition of the Fig 9 indicate that the major changes are large increases (from 26% to 76%) in the incidence of lymphocytes expressing the B220 marker, and a decrease in the incidence of cells expressing the macrophage/granulocyte markers MAC-1 and 8C5. There also was a decrease in the percentage of cells expressing sIg. Thus, these data correlate wcll with the morphologic results presented in Fig 8 and confirm a large increasc in immature B cells and a decrease in leukocytes bearing monocyte and granulocyte markers. In particular, the decreased frequency of 8C5 expression correlates with the decreased incidence of BM CFU progenitors previously reported (Figs 2.4, and 6) .
BM. The results of a representative experiment shown in
Effects of IL-7 administration in leukopenic mice. The administration of IL-7 results in a rapid systemic leukocytosis (Fig 1) through extramedullary myelopoiesis in the spleen (Figs 3, 5, and 7) and preferential stimulation of lymphopoicsis in the BM (Fig 9) . Thus, experiments were designed to determine whether the administration of IL-7 to leukopenic mice would accelerate the regeneration of leukocytes. The results shown in Fig 10 show that treatment of mice with IL-7 accelerates the recovery, and causes an overshoot, in total PBL. after the administration of Cy (Fig  10A) . Specifically, the administration of 1 kg, the lowest daily dose that significantly increased total PBL counts ( Fig  1) and altered CFU levels (Figs 4 and 5) in normal mice, caused a more rapid regeneration of total WBC in Cypretreated mice (Fig 10A) . By day 12 the total WBC count was 40% higher in thc IL-7-treated mice than in mice pretreated with Cy that did not receive IL-7 (P < .05), while at day 16 the WBC count was fivefold higher in the IL-7-treated mice (P < .01) and WBC levels in PBStreated mice remained suppressed to below pretreatment values. Because similar results were obtained by evaluation of the lymphocyte subset (P < .O1 on day 15), it is apparent that a major contribution to the recovery and overshoot in WBC is in the lymphocyte component. Similar lymphopoietic effects of IL-7 were observed when 5FU was used to induce leukopenia (Fig 10B) . Thus, IL-7 has leukopoietic effects in mice recovering from chemotherapy. 
DISCUSSION
The studies presented herein show that a 7-day course of IL-7 preferentially stimulated BM lymphopoiesis, induced a general leukocytosis, and increased the number of splenic CFU-GEMM and CFU-c. The number of BM CFU-GEMM and CFU-c colonies was reduced in a dose-and duration-dependent manner. These results contrast with the effects observed for IL-2, in which an increased level of splenic CFU-c was not accompanied by a proportionate decrease in BM CFU-c, suggesting that the regulation of myelopoiesis by IL-7 versus IL-2 may occur through somewhat different mechanisms. In fact, the amount of IL-2 used for this study (10 pg twice daily) is in the range of doses previously reported to cause vascular leak syndrome in mice:' suggesting that some of the effects of IL-2 could be related to this process. The administration of IL-7 in the same doses and schedules in this study resulted in no overt toxicity.
One hypothesis for the apparently opposing effects of IL-7 in the spleen and BM is that IL-7 has differential effects in those sites such that hematopoietic precursor cells in the BM are inhibited and those in the spleen are stimulated. A second hypothesis with regard to the effects of IL-7 on myelopoiesis would be that IL-7 induces progenitors for CFU-c, CFU-GEMM, and/or even earlier progenitors to exit the BM and localize in the spleen. We have also considered the possibility that the decreased frequency of myeloid progenitors in the BM of IL-7-treated mice may be due to their dilution by IL-7-induced lymphopoiesis. However, in our studies, as well as those of Morrissey et al," there was less than a twofold increase in total BM cellularity. Because there is an absolute decrease of up to 95% in the total CFU-c and CFU-GEMM isolated from paired femurs and tibias in the absence of a dramatic increase in BM cellularity, most of the IL-7-induced inhibition of CFU observed in our studies must be attributed to the loss or unresponsiveness of the progenitors. Recent evidence has shown that part of the leukocytosis induced in the spleens of normalz3 (Komschlies et al, manuscript submitted for publication) or leukopenicz4 mice is due to an increase in cells with a pre-B-cell phenotype. Our data extend these results to the BM, in which we observed an IL-7-induced increase in cells that were morphologically characterized as lymphocytes. Most of these lymphoid cells were phenotypically identified as early B cells. In parallel with the increase of B lymphopoiesis, there was a twofold to threefold reduction in the total number of cells that expressed the myelomonocytic markers MAC-1 and 8C5. In particular, there was a pronounced decrease in both 8C5 dull and 8C5 bright cells, suggesting a decrease in both immature myeloid cells as well as more mature granulocytes. 25 These results further support our conclusion that IL-7 reduces not only the frequency but also the total number of myelomonocytic progenitor cells in the BM. Because there is an increase in these progenitors in the spleen, it is possible that the myeloid progenitors are preferentially leaving the marrow and homing to the spleen. However, it is also possible that the decrease in BM myeloid progenitors seen after IL-7 treatment could arise as a result of stem cell selection. Alternatively, the existence of a stem cell common to lymphoid (B and T) and myeloid (erythroid, granulocytic, and megakaryocytic) lineages has recently been reported through transplantation studies using chromosomally marked marrow cells.= Thus, our results also could be interpreted to suggest that IL-7, acting either directly or indirectly, could preferentially shift this common BM progenitor away from the myeloid lineage that could trigger a compensatory burst of extramedullary hematopoiesis in the spleen.
We have been unable to show any direct effect of IL-7 in vitro on the basal or IL-3-driven proliferation of total BM cells, or on the number of CFU-GEMM, CFU-c, and HPP-CFC colonies obtained by culturing the BM marrow cells with different hematopoietic growth factors (data not shown). Similar results have been reported by who reported no evidence for a proliferative effect of IL-7 on myeloid cells, although BM T cells were stimulated. Thus, the in vivo effects of IL-7 on BM progenitor cells may For personal use only. on October 3, 2017. by guest www.bloodjournal.org From well be indirect, possibly through induction of other BM factors such as transforming growth factor p (TGFp)29 and negative regulatory protein (NRP)M that could inhibit the functions of hematopoietic precursor cell~,3l"~ or other factors that would induce them to leave the BM. The enhancing effects of IL-7 administration on extramedullary hematopoiesis also might be explained on the basis of an indirect stimulatory effect through factors induced in the spleen by IL-7. IL-7 already has been reported to induce IL-1, tumor necrosis factor (TNF), and IL-6 from human monocytes,% and all of these cytokines are known to stimulate some aspect of h e m a t o p o i e s i~.~~~~~ However, regardless of the mechanism, it appears that the effects of IL-7 on hematopoiesis could be of therapeutic value in promoting hematopoietic recovery in immunodeficient states, either iatrogenic in origin (eg, BM transplantation, chemotherapy and/or radiation therapy treatment of cancer) or disease-related (eg, acquired immunodeficiency syndrome, SCID). This hypothesis derives from our own studies reported herein, as well as the studies of Morrissey et a1,2l that showed either a more rapid recovery and/or overshoot in total WBC and lymphocytes in mice rendered leukopenic by Cy or 5FU. Thus, while the effects of IL-7 are mixed with respect to formation of myeloid CFU (ie, BM CFU are decreased while spleen CFU are increased), lymphopoiesis is clearly increased in the BM (Fig 9) , PB, and other sitesz (Komschlies et al, manuscript in preparation). This lymphopoietic effect of IL-7 is not restricted simply to B-cell lymphopoiesis because there is also an overall twofold to threefold increase in T cells, NK cells, and myelomonocytic cells in normal mice treated with IL-7 (Komschlies et al, manuscript submitted for publication). These observations suggest that further experiments be performed in normal and leukopenic mice to determine whether potent stimulators of myelopoiesis (eg, IL-3, IL-1, IL-6, or CSFs) could be used in concert with a lymphopoietic molecule such as IL-7 to rapidly restore various leukocyte subsets.
